Executive Vice President, Global Orphan Business Unit
Mr. Happel joined Horizon Pharma in October 2016 as part of the Raptor Pharmaceutical Corp. acquisition. He brings 30 years of experience in the healthcare industry into the role with the last 15 years dedicated to developing and commercializing treatments for rare diseases. Prior to joining Horizon, Mr. Happel was chief commercial officer at Raptor where he led the global commercialization of PROCYSBI® and QUINSAIR®. Prior to Raptor, he held chief commercial and corporate development roles at Allergen Research Corporation, a developer of treatments for food allergies, Dynavax Technologies, a drug development and vaccine company, and Aerovance, Inc., a biotechnology company. Mr. Happel also held senior-level leadership positions at Dr. Reddy’s Laboratories, Inc., Chiron Corporation, InterMune, Inc. and Parke-Davis/Pfizer, where he led the development and commercialization of several market-leading products, including TOBI® for cystic fibrosis and ACTIMMUNE® for the treatment of multiple orphan diseases. Mr. Happel received a Bachelor of Arts in chemistry from Indiana University and an MBA in marketing from Indiana State University.